Taken together, our data show that the RPE65-programmed BMDC are rapidly recruited to the retina via the ciliary/inner retinal vascular and reach the RPE layer within minutes following systemic administration further supporting the feasibility of this approach for treatment of RPE pathologies such as AMD. Here, RPE65 is linked to age-related macular degeneration.